ENDRA Life Sciences Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ENDRA Life Sciences Inc. (Nasdaq: NDRA) develops Thermo Acoustic Enhanced Ultrasound (TAEUS) technology to enhance clinical diagnostic ultrasound capabilities for non-invasive tissue visualization; the company's primary product, TAEUS Liver, quantifies liver fat fraction as a biomarker for metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), and metabolic dysfunction-associated steatohepatitis (MASH), formerly NASH, offering a point-of-care alternative to MRI and biopsy with improved accuracy via redesigned probes and proprietary algorithms; TAEUS also supports applications in tissue composition analysis, temperature monitoring during ablation therapies, vascular imaging, tissue perfusion, and potential detection of arterial plaque or internal bleeding. Founded in 2007 and headquartered in Ann Arbor, Michigan, ENDRA targets pharmaceutical companies, concierge medical practices, specialized clinics, and primary care providers in the diagnostics and research segment of the healthcare industry, with CE Mark approval enabling sales in Europe and ongoing pursuit of U.S. FDA De Novo clearance through a planned 250-subject multisite pivotal clinical trial. Recent developments include a October 2025 private placement raising up to $14.4 million led by institutional and cryptocurrency investors, the launch of a digital asset treasury strategy with an initial $3 million investment in HYPE tokens aligned with Arca Investment Management's DeFi holdings, significant cost reductions lowering quarterly operating expenses by 42% to $1.2 million and cash burn to $1.1 million, expansion of its global patent portfolio to 85 issued patents, a strategic pivot to subscription-based sales models with AI-enhanced next-generation TAEUS systems, and partnerships such as with the Arca U.S. Treasury Fund for yield generation to support commercialization.
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders
NDRA Stock Alert: Halper Sadeh LLC is Investigating Whether ENDRA Life Sciences Inc. is Obtaining a Fair Price for its Shareholders
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
ENDRA Life Sciences (NDRA) Expected to Announce Quarterly Earnings on Monday
NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision
ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
Critical Contrast: Pulse Biosciences (NASDAQ:PLSE) vs. ENDRA Life Sciences (NASDAQ:NDRA)
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA